This announcement is a separate document:
賽生藥業：(1) SILVER PEGASUS INVESTMENT LIMITED建議（根據公司法第86條）以協議安排方式將賽生藥業控股有限公司私有化；(2) 建議撤銷賽生藥業控股有限公司的上市地位；(3) 有關存續安排的特定交易；(4) 成立獨立董事委員會；(5) 委任獨立財務顧問；及 (6) 恢復股份買賣
SCICLONE PHARMA: (1) PROPOSAL FOR THE PRIVATISATION OF SCICLONE PHARMACEUTICALS (HOLDINGS) LIMITED BY SILVER PEGASUS INVESTMENT LIMITED BY WAY OF A SCHEME OF ARRANGEMENT (UNDER SECTION 86 OF THE COMPANIES ACT); (2) PROPOSED WITHDRAWAL OF LISTING OF SCICLON
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.